Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett
The Uromigos - Un podcast de The Uromigos
Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
